Skip to content

Healthy Effects of an Innovative Probiotic Pasta

Healthy Effects of an Innovative Probiotic Pasta

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02236533
Acronym
SFLABPASTA
Enrollment
40
Registered
2014-09-10
Start date
2014-03-31
Completion date
2015-03-31
Last updated
2018-11-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

CONSTIPATION, DYSLIPIDEMIA, INFLAMMATION, OBESITY

Brief summary

The aim of the project was the evaluation of the antioxidant and anti-inflammatory effects of a whole grain pasta, enriched in barley β-glucans and fortified with strains of Bacillus coagulans, versus a control wheat pasta on healthy volunteers, using a parallel randomized controlled trial.

Detailed description

Epidemiological evidences indicate that consumption of whole grains products is associated to a decreased risk for common chronic diseases, as cardiovascular diseases, diabetes, obesity, hypertension and metabolic syndrome. In the present study a whole grain pasta was supplemented with prebiotics and probiotics 'ad hoc' formulated. In detail, pasta was industrially developed after the identification of particular cultivars of wheat and barley, rich in carotenoids, β-glucans (2.6 g/100g pasta), not soluble fibers and antioxidants. Further, pasta was supplemented with spores of Bacillus coagulans, a putative probiotic microorganism, belonging to Lactobacillus family. It is well demonstrated the ability of this microorganism to survive to technological processes and to upper gastro-intesinal tract, in order to exert beneficial effects in the lower gut, as anti-microbial activity, increasing immunological defences as well as improvements in intestinal regularity. Conversely, the control pasta was made from the same cultivar of grain and by the same technological process, but without any supplementation. In this parallel randomized controlled one arm trial, 40 healthy volunteers were randomly allocated for the consumption of the two kind of pasta once a day, for 12 weeks. At the beginning of the study and every 4 weeks, subjects were asked to provide blood, urine and feces for the evaluation of: * blood inflammation markers; * blood lipid and carbohydrate profile; * blood and urine markers of cardiovascular risk; * feces profile of microbiota and detection of markers for the healthiness of the gut. In addition, volunteers filled in different questionnaires regarding their dietary habits, the physical activity and the gut healthiness.

Interventions

DIETARY_SUPPLEMENTwhole grain pasta

Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.

Sponsors

Universita di Verona
CollaboratorOTHER
University of Parma
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
30 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Overweight / Obesity * Lower consumers of fruit and vegetables

Exclusion criteria

* Antibiotic treatment within 3 months prior the pasta feeding * Chronic diseases * Surgeries * Consumer of whole grain products * Dieting * Pregnant or lactating

Design outcomes

Primary

MeasureTime frameDescription
Variation of plasma lipids12 weeksMeasure of plasma concentrations (mg/dL) of Total-, LDL-, and HDL-Cholesterol; Measure of plasma concentrations (µg/mL) of Non Esterified Fatty Acids (NEFA), Esterified Fatty Acids (EFA) and Short Chain Fatty Acids (SCFA). Statistical analysis of the primary outcome was performed within and between each single intervention-arm. Further, a post-hoc subdivision of the study participants by means of a BMI or glycaemia cut-off value was applied, and statistical differences of the primary outcome have been considered.
Variation of fecal microbiota composition12 weeksBy FISH (colony-forming unit, CFU/g). Statistical analysis of the primary outcome was performed within and between each single intervention-arm. Further, a post-hoc subdivision of the study participants by means of a BMI or glycaemia cut-off value was applied, and statistical differences of the primary outcome have been considered.
Variation of antioxidant activity on fecal waters12 weeksMeasure of fecal waters FRAP (µmol/L) and TEAC (µmol/L) concentrations. Statistical analysis of the primary outcome was performed within and between each single intervention-arm. Further, a post-hoc subdivision of the study participants by means of a BMI or glycaemia cut-off value was applied, and statistical differences of the primary outcome have been considered.

Secondary

MeasureTime frameDescription
Variation of body circumferences12 weeksMeasure of waist and hip circumferences (mm). Statistical analysis of the secondary outcome was performed within and between each single intervention-arm. Further, a post-hoc subdivision of the study participants by means of a BMI or glycaemia cut-off value was applied, and statistical differences of the secondary outcome have been considered.
Variation of body weight12 weeksMeasure of body weight (kg).
Variation of urine antioxidant marker12 weeksMeasurement of betaine in urine (mmol/L). Statistical analysis of the secondary outcome was performed within and between each single intervention-arm. Further, a post-hoc subdivision of the study participants by means of a BMI or glycaemia cut-off value was applied, and statistical differences of the secondary outcome have been considered.
Variation of serum inflammatory marker concentration12 weeksMeasure of serum IL-2, IL-4, IL-5, IL-6, IL-10, IL-12, IFN-γ,TNF-α, PAI-1, Ghrelin, Leptin, Visfatin, Resistin concentrations (pg/mL). Statistical analysis of the secondary outcome was performed within and between each single intervention-arm. Further, a post-hoc subdivision of the study participants by means of a BMI or glycaemia cut-off value was applied, and statistical differences of the secondary outcome have been considered.
Variation of blood pressure12 weeksMeasure of blood pressure (mmHg). Statistical analysis of the secondary outcome was performed within and between each single intervention-arm. Further, a post-hoc subdivision of the study participants by means of a BMI or glycaemia cut-off value was applied, and statistical differences of the secondary outcome have been considered.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026